Sign In
Buy CTKB
Cytek Biosciences Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.120 |
| EPS Surprise | -50.00% |
| Revenue estimate | 44.233M |
| Revenue actual | 44.135M |
| Revenue Surprise | -0.222% |
| Release date | Feb 26, 2026 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0100 |
| EPS Surprise | 50.00% |
| Revenue estimate | 57.15M |
| Revenue actual | 62.141M |
| Revenue Surprise | 8.73% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0100 |
| EPS Surprise | -200.00% |
| Revenue estimate | 58.8M |
| Revenue actual | 52.293M |
| Revenue Surprise | -11.07% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.0200 |
| EPS actual | $0.0100 |
| EPS Surprise | 150.00% |
| Revenue estimate | 46.349M |
| Revenue actual | 45.602M |
| Revenue Surprise | -1.61% |
Last 4 Quarters for Cytek Biosciences
Below you can see how CTKB performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $3.89 |
| EPS estimate | -$0.0200 |
| EPS actual | $0.0100 |
| EPS surprise | 150.00% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $3.60 |
| Aug 01, 2025 | $3.64 |
| Aug 04, 2025 | $3.84 |
| Aug 05, 2025 | $3.88 |
| Aug 06, 2025 | $3.89 |
| Aug 07, 2025 | $4.11 |
| Aug 08, 2025 | $4.03 |
| Aug 11, 2025 | $3.79 |
| Aug 12, 2025 | $4.03 |
| 4 days before | 8.06% |
| 4 days after | 3.60% |
| On release day | 5.66% |
| Change in period | 11.94% |
| Release date | Nov 05, 2025 |
| Price on release | $4.01 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0100 |
| EPS surprise | -200.00% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $3.82 |
| Oct 31, 2025 | $3.90 |
| Nov 03, 2025 | $3.94 |
| Nov 04, 2025 | $3.91 |
| Nov 05, 2025 | $4.01 |
| Nov 06, 2025 | $4.54 |
| Nov 07, 2025 | $4.62 |
| Nov 10, 2025 | $4.75 |
| Nov 11, 2025 | $4.79 |
| 4 days before | 4.97% |
| 4 days after | 19.45% |
| On release day | 13.22% |
| Change in period | 25.39% |
| Release date | Feb 26, 2026 |
| Price on release | $4.40 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0100 |
| EPS surprise | 50.00% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $4.43 |
| Feb 23, 2026 | $4.39 |
| Feb 24, 2026 | $4.36 |
| Feb 25, 2026 | $4.37 |
| Feb 26, 2026 | $4.40 |
| Feb 27, 2026 | $4.48 |
| Mar 02, 2026 | $4.43 |
| Mar 03, 2026 | $4.44 |
| Mar 04, 2026 | $4.41 |
| 4 days before | -0.677% |
| 4 days after | 0.227% |
| On release day | 1.82% |
| Change in period | -0.451% |
| Release date | May 07, 2026 |
| Price on release | $4.92 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.120 |
| EPS surprise | -50.00% |
| Date | Price |
|---|---|
| May 01, 2026 | $4.62 |
| May 04, 2026 | $4.66 |
| May 05, 2026 | $4.78 |
| May 06, 2026 | $4.94 |
| May 07, 2026 | $4.92 |
| May 08, 2026 | $4.61 |
| May 11, 2026 | $4.12 |
| May 12, 2026 | $4.04 |
| May 13, 2026 | $3.68 |
| 4 days before | 6.49% |
| 4 days after | -25.20% |
| On release day | -6.30% |
| Change in period | -20.35% |
Cytek Biosciences Earnings Call Transcript Summary of Q1 2026
Cytek reported Q1 2026 revenue of $44.1M, up 6% year-over-year, driven by a strong U.S. rebound (U.S. revenue +32% to $24.4M). The company added 125 instruments in the quarter, bringing the installed base to 3,789, and highlighted continued traction for the Aurora Evo analyzer. Recurring revenue (reagents + service) strengthened to 35% of total revenue on a trailing 12-month basis and grew 19% year-over-year, with service revenue up 15% and reagent revenue up ~16%. Geographically, EMEA was down 7% due to Middle East conflict-related disruption and a shipment delay, and APAC was down 13% primarily due to timing in China (excluding China APAC showed strong growth). GAAP gross margin was 48%; GAAP net loss was $18.9M and adjusted EBITDA loss was $9.1M (driven by higher operating expenses including legal costs). Cash and marketable securities were $262.2M. The company reaffirmed full-year 2026 revenue guidance of $205M–$212M (2%–5% growth) and expects to deliver positive adjusted EBITDA for the full year, with margins and adjusted EBITDA anticipated to improve in later quarters due to seasonality and revenue growth. Management is reorganizing into three customer-aligned business units to accelerate growth in reagents, low/mid-tier instruments, and research technology, and is focused on expanding clinical and translational opportunities.
